

APONTIS PHARMA AG Share buyback: Disclosure pursuant to Article 5 paragraph 1 lit. b) and paragraph 3 of the Regulation (EU) No. 596/2014 (MAR) in connection with Article 2 paragraph 2 and paragraph 3 of the Delegated Regulation (EU) No. 2016/1052

Purchase of own shares - 3rd Interim notification

Monheim am Rhein, 04 April 2022. In the period from 28 March 2022 up to and including 01 April 2022, a total of 30,003 shares were purchased under the Share Buyback Program 2022. The launch and the details of the Share Buyback Program 2022 were published by way of an announcement dated 15 March 2022 pursuant to Article 5 paragraph 1 of Regulation (EU) No. 596/2014 and Article 2 paragraph 1 of the Delegated Regulation (EU) No. 2016/1052.

The total number of shares purchased in the period from 28 March 2022 up to and including 01 April 2022 per day, exchange, average price and volume in euros are as follows:

Date	Total number of shares purchased (number)	Average price (Euro)	Exchange	Volume (EUR) ¹
28/03/2022	5,610	10.9570	Xetra	61,469.30
29/03/2022	5,961	10.9738	Xetra	65,415.10
30/03/2022	6,555	10.9295	Xetra	71,643.50
31/03/2022	7,838	10.9955	Xetra	86,182.80
01/04/2022	4,039	11,5263	Xetra	46,554.75

1) Excluding acquisition costs

The total number of shares purchased to date as part of the Share Buyback Program 2022 up to and including 01 April 2022 amounts to 59,029 shares.

The share buyback was carried out by Hauck Aufhäuser Lampe Privatbank AG.



Further details on the Share Buyback Program 2022 and the above transactions are published under the Corporate Governance section of the Company's Investor Relations website in accordance with Article 5 of Regulation (EU) No. 596/2014 and pursuant to Delegated Regulation (EU) No. 2016/1052 (<https://ir.apontis-pharma.de/websites/apontispharma/English/4000/corporate-governance.html>).